SCHEMBL175638

SCHEMBL175638

c1ccc(N(c2ccccc2)c2cccc(-c3nnc(-c4ccccc4-c4nnc(-c5cccc(N(c6ccccc6)c6ccccc6)c5)o4)o3)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 17/20 0.50
NPC1 O15118 15/20 0.50
SMN1; SMN2 Q16637 10/20 0.50
ALDH1A1 P00352 7/20 0.50
HPGD P15428 6/20 0.50
TSHR P16473 5/20 0.50
TP53 P04637 3/20 0.50
NFKB1 P19838 3/20 0.50
NFKB2 Q00653 3/20 0.50
RELA Q04206 3/20 0.50
MECP2 P51608 1/20 0.50
KDM4E B2RXH2 4/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 3/20 0.46
LMNA P02545 1/20 0.46
HSD17B10 Q99714 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21311967 0.94 RAB9A (0.46) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL17951436 0.93 NPC1 (0.57) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL14465695 0.92 NPC1 (0.61) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL173684 0.92 NPC1 (0.55) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL502474 0.90 NPC1 (0.59) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL14466355 0.90 NPC1 (0.59) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL175637 0.85 RAB9A (0.56) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL14466543 0.84 RAB9A (0.55) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL17955168 0.84 RAB9A (0.55) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL14465523 0.84 NPC1 (0.55) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609258-B2 Light emitting devices and compositions NITTO DENKO CORPORATION (JP) 2013-12-17 US claimed
US-8597803-B2 Light emitting devices and compositions NITTO DENKO CORPORATION (JP) 2013-12-03 US claimed
US-20120305895-A1 LIGHT EMITTING DEVICES AND COMPOSITIONS NITTO DENKO CORPORATION (JP) 2012-12-06 US claimed
US-20120273765-A1 LIGHT EMITTING DEVICES AND COMPOSITIONS NITTO DENKO CORPORATION (JP) 2012-11-01 US claimed
US-20090179552-A1 LIGHT EMITTING DEVICES AND COMPOSITIONS NITTO DENKO CORPORATION (JP) 2009-07-16 US claimed
WO-2009064661-A1 LIGHT EMITTING DEVICES AND COMPOSITIONS NITTO DENKO CORPORATION (JP) 2009-05-22 WO claimed
US-20090066234-A1 LIGHT EMITTING DEVICES AND COMPOSITIONS NITTO DENKO CORPORATION (JP) 2009-03-12 US claimed
WO-2009006550-A1 LIGHT EMITTING DEVICES AND COMPOSITIONS NITTO DENKO CORPORATION (JP) 2009-01-08 WO claimed
WO-2012030421-A1 DEVICES AND METHODS QD VISION, INC. (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090066234-A1 LIGHT EMITTING DEVICES AND COMPOSITIONS MAP1LC3A, MAP1LC3C, CRY1 RAB9A 962/4885NPC1 3835/4885SMN1; SMN2 2322/4885
US-20120305895-A1 LIGHT EMITTING DEVICES AND COMPOSITIONS ILK, CRY1, IK RAB9A 512/4885NPC1 3013/4885SMN1; SMN2 2301/4885
US-20090179552-A1 LIGHT EMITTING DEVICES AND COMPOSITIONS CYBA, LIMA1, CRY1 RAB9A 850/4885NPC1 3302/4885SMN1; SMN2 2606/4885
US-20120273765-A1 LIGHT EMITTING DEVICES AND COMPOSITIONS CYBA, LIMA1, CRY1 RAB9A 850/4885NPC1 3302/4885SMN1; SMN2 2606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.